Johnson & Johnson met main goal in its oral treatment trial for ulcerative colitis

Johnson & Johnson (NYSE:JNJ) said on Monday that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative colitis, met main goal.

JNJ stock up about 1% in morning trade.

The trial showed positive clinical responses